United States Patent 5,775,321: Scope, Claim Architecture, and US Landscape

US Drug Patent 5,775,321 claims an aerosol canister structure that uses two seals with differential barrier/lability behavior against components in a medicinal aerosol formulation. The independent claim is directed to the canister hardware and seal arrangement at the valve interface, with dependent claims narrowing elastomer chemistry, optional tack reduction, propellant identity (HFCs), and formulation add-ons (ethanol, polar cosolvent, medicament). The claim set also contains an alternate structural dependent track that specifies a ferrule geometry (cylindrical skirt) and a different sealing interface stack (ferrule gasket and o-ring).

What is the core inventive concept in 5,775,321?

The patent’s dominant technical theme is a valve ferrule occluding a vial opening, creating a chamber defined by the vial body, first seal, and valve ferrule, and ensuring seal-to-formulation selectivity:

The first seal provides a barrier to one or more medicinal aerosol components.
The second seal is more labile (more permeable/reactive/compatible loss) to those same components than the first seal.
The valve ferrule and vial body seal in opposing sealing engagement with each of the first and second seals.

Independent Claim 1 operationalizes this by tying a two-seal architecture to component-specific transport or interaction in the aerosol chamber.

Independent Claim 9 is a parallel, more mechanical gasket stack embodiment: it specifies a vial rim, valve ferrule gasket surface, ferrule gasket, and an o-ring, plus a ferrule flange sealing engagement and the same ferrule skirt geometry.

Independent Claim 18 shifts from “medicinal aerosol formulation” generally to explicit HFC propellant in the chamber and keeps the dual-seal interface concept.

How does the claim set map structurally?

Claim block A: Dual-seal barrier/lability architecture at the vial opening interface (Claims 1 and 18)

Claim	Core requirement	Formulation scope	Key interface mechanics
1	Vial body + two seals + valve ferrule occluding vial opening; chamber formed by vial body, first seal, valve ferrule; ferrule and vial body oppose-seal with each seal	“One or more medicinal aerosol formulation components” (not limited to HFC in claim 1)	First seal provides barrier; second seal is more labile to the relevant components
18	Same interface and chamber concept; chamber includes hydrofluorocarbon propellant	HFC propellant in chamber	Dual sealing engagement with first and second seals; first seal barrier concept retained via Claim 24

Claim block B: Elastomer chemistry and tack control on the barrier seal (Claims 2-4, 10-12, 17, 27-28)

Two distinct elastomer chemistries appear repeatedly as “seal chemistry” options:

Ethylene-based TPE: about 80–95% ethylene with 5–20% comonomers selected from 1-butene, 1-hexene, 1-octene.
Styrenic TPE: styrene-ethylene/butylene-styrene (SEBS/SBS-type family) wording used as the other option.

Then there is a functional tack reduction narrowing:

Talc added to the “first seal” or “ferrule gasket” to reduce and/or eliminate tack.

Claim block C: Propellant and formulation add-ons (Claims 6-7, 15-16, 20-21, 22-23)

The propellant language is tightly focused on two HFCs:

1,1,1,2-tetrafluoroethane (HFC-134a)
1,1,1,2,3,3,3-heptafluoropropane (HFC-227ea)

Optional formulation features:

Ethanol (explicit dependent claims)
Generic “polar cosolvent” (dependent chain to ethanol)
“Medicament”
“Metered dose valve” as the ferrule variant

Claim block D: Ferrule geometry and sealing stack variant (Claims 9-13)

Claim 9 specifies a ferrule cylindrical skirt extending along the exterior or interior (or a complementary radial skirt). It also defines a sealing stack:

Valve ferrule has annular gasket surface and flange
Ferrule gasket and o-ring seal
Gasket surface of valve ferrule and annular rim are in opposing sealing engagement with ferrule gasket
Valve ferrule occludes the opening to define chamber
Flange extends along exterior wall; vial body and flange are in opposing sealing engagement with o-ring

What is the detailed scope of each major claim feature?

1) Dual-seal “barrier vs labile” concept (Claim 1)

Claim 1 requires, in combination:

Canister hardware
- Vial body with vial opening
- Valve ferrule occludes the opening
- Chamber defined by vial body, first seal, valve ferrule
Two sealing interfaces
- Valve ferrule and vial body in opposing sealing engagement with each of:
  - first seal
  - second seal
Barrier/lability differentiation
- First seal provides a barrier to one or more medicinal aerosol formulation components
- Second seal is more labile to the same component(s) than the first seal
Ferrule skirt geometry
- Ferrule comprises a cylindrical skirt extending along the exterior or interior of vial body, or along a complementary radial skirt

Business implication: claim 1 reads like a claim drafted for materials compatibility and permeability control. The “barrier vs labile” feature is a functional limitation tied to component classes (not limited to a named propellant in claim 1), which can broaden infringement arguments to different medicinal formulations so long as the first/second seals exhibit the differential behavior.

2) Elastomer barrier seal chemistry and tack control (Claims 2-4)

Claim 2 fixes first seal composition to an ethylene-based TPE:
- 80–95% ethylene
- 5–20% comonomers from 1-butene, 1-hexene, 1-octene
Claim 3 allows optional talc in an amount effective to reduce and/or eliminate tack.
Claim 4 provides an alternative seal chemistry:
- first seal comprises styrene-ethylene/butylene-styrene copolymer

Business implication: the claim set provides multiple “paths” for claim coverage. A design that changes seal polymer chemistry may avoid Claim 2/3 but may still land in Claim 4’s styrenic pathway or in Claim 1’s broader “barrier vs labile” functional requirement.

3) Chamber contains medicinal aerosol formulation (Claim 5)

Claim 5 is a straightforward limitation: chamber contains a medicinal aerosol formulation. It functions as a bridge for the dependent propellant claims.

4) HFC propellant limitation (Claims 6-7 and 15-16 and 18-19)

Two HFCs repeatedly appear:

Claim 6 / Claim 15: propellant comprises HFC-134a or HFC-227ea
Claim 7 / Claim 16: formulation further comprises ethanol
Claim 18 / Claim 19: chamber containing an HFC aerosol formulation, with the same two HFC options.

Business implication: this creates a clearly defensible formulation-specific subset. If a competing canister uses these HFCs plus a dual seal barrier/lability architecture, it faces the tightest claim convergence.

5) Alternative “integral seals” and gasket family (Claim 8)

Claim 8 requires:

first seal comprises either:
- ethylene/comonomer TPE, or
- styrene-ethylene/butylene-styrene copolymer
first and second seals are integral with one another

Business implication: a competitor using independent, non-integral seals can steer around Claim 8 while still potentially falling under Claim 1 depending on how “integral” is construed.

6) Second seal elastomer options (Claim 17)

Claim 17 specifies second seal comprises neoprene, butyl rubber, or nitrile rubber.

Business implication: Claim 1 itself does not restrict materials; Claim 17 narrows it. But because Claim 17 is dependent, it only matters if the claim is otherwise satisfied.

7) Ferrule skirt + alternative sealing stack (Claims 9-13)

Claim 9 defines a different but related structural embodiment:

vial body: exterior walls and an annular rim defining opening
valve ferrule: annular gasket surface and flange
ferrule gasket and o-ring seal
opposing sealing engagement:
- gasket surface of ferrule with annular rim via ferrule gasket
- vial body with flange via o-ring
valve ferrule occludes opening to define chamber
ferrule includes a cylindrical skirt extending along exterior or interior or complementary radial skirt

Dependent claims refine this stack:

Claim 10: ferrule gasket is ethylene-based TPE (80–95% ethylene; 5–20% of the same comonomers)
Claim 11: ferrule gasket may include talc to reduce/eliminate tack
Claim 12: ferrule gasket is styrene-ethylene/butylene-styrene copolymer
Claim 13: o-ring seal comprises nitrile rubber

Business implication: claim 9 is likely targeted at a recognizable commercial nozzle/valve sealing stack. A canister using different gasket interfaces, or omitting one of the gasket/o-ring sealing layers, may escape this dependent set but still face Claim 1/18 barrier/lability coverage.

8) HFC formulation plus polar cosolvent and medicament (Claims 20-23)

Claim 20: chamber contains a polar cosolvent
Claim 21: polar cosolvent is ethanol
Claim 22: chamber includes a medicament
Claim 23: valve ferrule includes a metered dose valve

Business implication: these claims create coverage hooks for formulation packages and delivery systems (metered dose valve).

9) Broad “first seal provides barrier” recapture for the HFC track (Claim 24)

Claim 24 restates:

first seal provides barrier to aerosol components to which second seal is more labile

This ties the functional barrier/lability element back into the HFC-specific independent claim lineage.

10) Seal material form constraints (Claims 25-29)

Claim 25: first seal includes a thermoplastic elastomer
Claim 26: second seal includes a thermoset elastomer
Claim 27: first seal is ethylene/comonomer TPE (same ranges)
Claim 28: first seal is styrene-ethylene/butylene-styrene copolymer
Claim 29: first and second seals are both o-rings

Business implication: Claim 29 is a high-convergence design possibility for competitors using dual o-ring seals at valve interfaces, as long as the barrier/lability functional limitation is met.

What is the patent landscape likelihood around this claim scope?

Landscape segmentation by claim “clusters”

Given the claim set, the landscape divides into four practical competitive zones:

Valve/vial sealing hardware with dual seals
- Central to Claim 1 and Claim 18/24
- Likely common in aerosol engineering patents (nozzle interfaces, ferrule/vial rim seals)
Seal materials engineered for permeability/tack
- Barrier/lability functional limitation in Claim 1/24
- Specific polymers and talc in Claims 2-4, 3, 10-12, 11
HFC aerosol formulations with specific HFCs and ethanol
- HFC-134a and HFC-227ea in Claims 6-7 and 15-16; Claim 18/19; polar cosolvent/ethanol in Claims 20-21
Metered dose valve integration
- Claim 23

Design-around pressure points

Remove or change the dual-seal barrier/lability feature: altering the sealing architecture so it is not “first barrier vs second labile” materially undermines Claim 1 and Claim 24 coverage.
Use different polymer families for the barrier seal: bypasses Claims 2/3/4 and Claims 10-12/27-28 dependent sets, though Claim 1 remains functional.
Avoid the named HFCs: sidesteps Claims 6-7, 15-16, 18-19, and dependent HFC-related claims.
Avoid the specified ferrule skirt geometry: can narrow Claim 1/9 coverage.
Avoid the exact sealing stack (Claim 9): change gasket and o-ring interface design to escape the Claim 9-dependent pathway.

How does the claim set constrain “infringing structure”? (Claim scope summary tables)

Claim scope matrix by structural element

Structural element	Appears in	What it does in infringement terms
Vial body + vial opening	1, 5, 9, 18	Baseline aerosol canister structure
Valve ferrule occludes opening	1, 9, 18	Defines chamber closure at valve interface
Chamber defined by vial body + first seal + ferrule	1, 18	Anchors the claimed sealing volume
Two seals where ferrule and vial body seal against each of first and second	1, 18	Requires dual sealing engagement, not just one gasket
First seal barrier; second seal more labile	1, 24	Functional materials barrier limitation
Ferrule cylindrical skirt	1, 9	Geometry limitation that can be design-around target
First seal TPE polymer identity (ethylene/comonomer or styrenic)	2-4, 8, 27-28	Dependent chemical composition narrowing
Talc for tack reduction	3, 11	Dependent functional additive limitation
HFC propellant identity	6-7, 15-16, 18-19	Formulation-specific limitation
Ethanol / polar cosolvent	7, 16, 20-21	Formulation sub-scope narrowing
Medicament	22	Formulation product class narrowing
Metered dose valve	23	Delivery sub-scope narrowing
Alternative gasket stack with ferrule gasket + o-ring	9, 10-13	Dependent structural variant

What is the practical “claim hierarchy” (independent-to-dependent convergence)?

Tightest convergence path (highest-risk design overlap)

A product that simultaneously matches:

dual seals with first barrier and second more labile (Claim 1 or Claim 18 plus 24)
barrier seal polymer chemistry (Claim 2 or 4, or Claim 10-12)
specific HFC propellant (Claim 6 or 15 or Claim 18-19)
ethanol as cosolvent (Claim 7 or 16 or Claim 21)
ferrule skirt geometry (Claim 1/9)
and optionally metered dose valve (Claim 23)

hits the most dependent claim layers.

Medium convergence path

A canister that matches dual-seal barrier/lability and ferrule skirt but uses:

a different barrier polymer chemistry (avoid Claims 2-4/10-12/27-28)
different cosolvent (avoid ethanol claims) can still remain at risk under Claim 1/24 due to the barrier/lability functional limitation.

Key Takeaways

US 5,775,321 is a canister-and-seal interface patent built around two seals where the first seal is a barrier and the second is more labile to one or more aerosol formulation components.
The claims incorporate a ferrule skirt geometry and require valve ferrule occlusion to define a chamber with dual sealing engagement.
The tightest formulation coverage ties to HFC-134a and HFC-227ea, with ethanol and optional polar cosolvents (ethanol-specific) and medicament.
Multiple dependent claims narrow to specific seal elastomer chemistries (ethylene/comonomer TPE; styrenic TPE) and tack reduction with talc, plus a structural stack variant using ferrule gasket and o-ring.
The highest infringement exposure scenario is a design that retains the dual-seal barrier/lability functionality, uses HFC-134a or HFC-227ea, and aligns polymer/tack/ferrule skirt and (optionally) metered-dose valve elements with the dependent claims.

FAQs

1) Does 5,775,321 require that the propellant be an HFC in the broadest independent claim?

No. Claim 1 recites a medicinal aerosol formulation generally; the explicit HFC limitation is tied to the HFC-focused independent claim (Claim 18) and its dependents.

2) What seals are involved in the claimed barrier/lability concept?

Claim 1 requires a first seal (barrier) and a second seal (more labile), with the valve ferrule and vial body in opposing sealing engagement with each seal.

3) Which propellants are explicitly listed?

The claims name 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoropropane as the HFC propellant options.

4) Are ethanol and polar cosolvents optional or required?

They are optional dependent features. Ethanol is required only in the dependent claims that specify it, while polar cosolvent is required only in those dependents.

5) What is the role of talc?

Talc is used as an additive to the specified elastomer seal (first seal or ferrule gasket) to reduce and/or eliminate tack in dependent claims.

References

[1] United States Patent No. 5,775,321 (claims provided in prompt text).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	6665994	⤷ Start Trial
Australia	695969	⤷ Start Trial
Canada	2161632	⤷ Start Trial
Germany	69406916	⤷ Start Trial
Germany	69701051	⤷ Start Trial
European Patent Office	0697002	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,775,321

Summary for Patent: 5,775,321